356068-97-8Relevant articles and documents
Peptide-Drug conjugate gnrh-sunitinib targets angiogenesis selectively at the site of action to inhibit tumor growth
Argyros, Orestis,Karampelas, Theodoros,Asvos, Xenophon,Varela, Aimilia,Sayyad, Nisar,Papakyriakou, Athanasios,Davos, Constantinos H.,Tzakos, Andreas G.,Fokas, Demosthenes,Tamvakopoulos, Constantin
, p. 1181 - 1192 (2016)
The potential to heighten the efficacy of antiangiogenic agents was explored in this study based on active targeting of tumor cells overexpressing the gonadotropin-releasing hormone receptor (GnRH-R). The rational design pursued focused on five analogues
AMP-ACTIVATED PROTEIN KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME
-
Page/Page column 64-65; 69-70, (2021/01/23)
The present disclosure relates to compounds of Formula (I): (I); stereoisomers thereof, prodrugs thereof, and pharmaceutically acceptable salts thereof. The present disclosure also relates to uses of the compounds, e.g., to inhibit AMP-Activated protein kinase (AMPK) and treat cancer in a subject.
N-desethylsunitinib phosphoramide derivatives and preparation method thereof
-
Paragraph 0055; 0063-0068, (2019/08/20)
The invention relates to N-desethylsunitinib phosphoramide derivatives represented by a general formula (I) shown in the description, stereoisomers of the derivatives or pharmaceutically-acceptable salts of the derivatives, a preparation method of the der
